Greenfield-based Elanco Animal Health Inc. (NYSE: ELAN) is reporting a third quarter net loss of $104 million, compared to a loss of $135 million during the same period a year ago. The company says Q3 revenue was $1.3 billion, an increase of 27%, caused by increased scale and diversification resulting from the Bayer Animal Health acquisition in August 2020.
Elanco Chief Executive Officer Jeff Simmons says business continues to show good momentum and strong fundamentals since closing the Bayer acquisition.
“…with our fourth consecutive quarter exceeding our top-line growth expectations while concurrently making steady headway toward our long-term margin targets,” said Simmons. “Our teams remain focused on finishing 2021 well and continuing to drive growth in 2022.”
Click here to view the full report.